Cancer News

  • Playlist
  • Download
  • Embed
    <iframe src="" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">

Last week the FDA approved Erbitux (ERB-ih-tux) a so-called "targeted cancer therapy" that could help people in the late stages of colon cancer. Erbitux is the latest addition to a relatively new class of cancer-fighting drugs called monoclonal antibodies. In this hour, we'll take a look at these, and other new cancer drugs. How are they changing the way we fight cancer? We'll also take a look at the link between chronic antibiotic use and breast cancer.


Dr. Larry Norton
*Deputy physician in chief for breast cancer programs at the *Memorial Sloan Kettering Cancer Center in New York

Dr. Brian Druker
*Associate professor, medicine (hematology and medical oncology), biochemistry and molecular biology, and cell and developmental biology at the Oregon Health Science University, School of Medicine
*Leader, Oregon Cancer Center Hematologic Malignancies Program in Portland, Ore.



Please keep your community civil. All comments must follow the Community rules and terms of use, and will be moderated prior to posting. NPR reserves the right to use the comments we receive, in whole or in part, and to use the commenter's name and location, in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

NPR thanks our sponsors

Become an NPR sponsor

Support comes from